Lenvatinib - E7080

Based on 20 reference(s) in Google Scholar 80 100 20

Axon 3165

CAS [417716-92-8]

MF C21H19ClN4O4
MW 426.85

  • Purity: 98%
  • Soluble in DMSO



Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. Lenvatinib inhibited Flt-1 (VEGFR1), KDR (VEGFR2) and Flt-4 (VEGFR3) with IC50 values of 22, 4.0 and 5.2 nM, respectively. Lenvatinib has potent antitumor activity against human H146, a SCLC cell line in mice based on angiogenesis inhibition via both KDR and KIT signaling, compared to single inhibition of either KDR or KIT signaling.

KEYWORDS: Lenvatinib | supplier | RTK inhibitor | E7080 | E 7080 | E-7080' | CAS [417716-92-8] | [857890-39-2] | VEGF | VEGFR | Inhibitor | Receptors

Size Unit Price Stock
10 mg €70.00 In Stock
50 mg €150.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...